Shares of French biotech Abivax (ABVX) climbed in Paris on Wednesday, in a move Reuters attributed to market speculation about a potential takeover bid from weight-loss drugmaker Eli Lilly (LLY).
The clinical-stage biotech, whose lead asset obefazimod is designed to target